Emerging therapeutic targets in endometrial cancer

@article{Dedes2011EmergingTT,
  title={Emerging therapeutic targets in endometrial cancer},
  author={Konstantin J. Dedes and D Wetterskog and Alan Ashworth and Stanley B. Kaye and Jorge Sergio Reis-Filho},
  journal={Nature Reviews Clinical Oncology},
  year={2011},
  volume={8},
  pages={261-271}
}
Endometrial cancer comprises a heterogeneous group of tumors, with distinct risk factors, clinical presentation, histopathological features and molecular characteristics. Currently, treatment of metastatic or recurrent disease is based on conventional chemotherapy combination regimens. Advances in the understanding of the molecular pathology of the two types of endometrial carcinoma—type I (endometrioid) and type II (non-endometrioid)—have underpinned the first steps in the development and… Expand
The emerging role of precision medicine in the treatment of endometrial cancer
TLDR
This paper describes molecular pathways including PI3 K/AKT/mTor, VEGF, and angiogenesis, HER2/neu and EGFR, various endocrine therapies and immune checkpoint inhibitors and Immunotherapy remains the most promising treatment for advanced endometrial cancers. Expand
Markers for individualised therapy in endometrial carcinoma.
TLDR
The present knowledge regarding biomarkers in endometrial carcinoma is summarized, assessing how such markers could be applied to address key clinical challenges for the treatment of this disease. Expand
Molecular targets and targeted therapeutics in endometrial cancer
TLDR
The clinicopathological and molecular heterogeneity of endometrioid cancer needs to be taken into account in the design of future clinical trials as well as the incorporation of robust biomarkers for the success of therapeutic strategies in endometrial cancer. Expand
Targeting molecular pathways in endometrial cancer: a focus on the FGFR pathway.
TLDR
The fibroblast growth factor receptor (FGFR) pathway is one of several signaling pathways that have been implicated in the pathogenesis and progression of endometrial cancer and the activity of novel FGFR-targeted agents in preclinical endometrian cancer models and clinical trials will be reviewed. Expand
Emerging molecular-targeted therapies—the challenging case of endometrial cancer
TLDR
This review aims to summarize the latest published and ongoing trials on targeted therapies in endometrial cancer. Expand
Molecular-targeted therapies and precision medicine for endometrial cancer.
TLDR
The previous efforts, including antiangiogenesis therapy, PI3K/AKT/mTOR pathway inhibitor treatment and epidermal growth factor receptor inhibitor treatment are highlighted and reports on ongoing phase 2 clinical trials, including immune checkpoint inhibitor and PARP inhibitor are reported on. Expand
Clinical actionability of molecular targets in endometrial cancer
TLDR
The overarching molecular features of endometrial cancers are summarized and recent studies assessing the potential clinical utility of specific molecular features for early detection, disease risk stratification and directing targeted therapies are highlighted. Expand
Emerging strategies for targeting PI3K in gynecologic cancer.
TLDR
Preclinical data is presented that supports the role of the PI3K pathway in ovarian, endometrial and cervical cancers and the rationale behind ongoing clinical trials utilizing novel agents in concert with PI3k pathway inhibitors to reverse resistance in populations with and without gain of function alterations in this oncogenic signaling cascade is discussed. Expand
New candidate therapeutic agents for endometrial cancer: Potential for clinical practice (Review)
TLDR
The background and early clinical evidence for metformin, microRNAs involved in the molecular mechanisms of oncogenesis and progression, and HDAC inhibitors that block the growth of cancer cells by transcriptional elevation of tumor-suppressor genes, cell cycle arrest and induction of apoptosis are reviewed. Expand
Towards individualisation of treatment in endometrial cancer
TLDR
Activation of the P13K pathway has been observed in ~30% oftype 1 endometrial cancers and 20% of type 2 endometrian cancers, although mTOR-directed targeted therapy has shown only modest activity to date, which provides interesting challenges for a personalised approach to the treatment of these tumours. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 178 REFERENCES
Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma.
TLDR
A potential role for therapeutic agents targeting the PI3K-AKT-mTOR pathway, such as rapamycin, as well as possible targets of EGFR in the treatment of uterine serous carcinoma is suggested. Expand
Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.
  • A. Bardelli, S. Siena
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2010
TLDR
The evidence that mCRCs respond differently to EGFR-targeted agents and that the tumor-specific response has a genetic basis is discussed and it is suggested that CRCs lacking oncogenic alterations in these four genes have the highest probability of response to anti-EGFR therapies and are defined as "quadruple negative". Expand
Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148.
  • A. Oza, E. Eisenhauer, +11 authors A. Fyles
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2008
TLDR
Erlotinib is well tolerated with an overall objective response rate of 12.5% and molecular analysis did not identify EGFR mutations in responders or correlation of response with gene amplification. Expand
A phase II study of temsirolimus (CCI-779) in patients with metastatic and/or locally advanced recurrent endometrial cancer previously treated with chemotherapy: NCIC CTG IND 160b
TLDR
This trial was designed to assess the level of activity in patients who had previously received chemotherapy and demonstrated promising activity inhibition of mTOR with temsirolimus, an ester derivative of rapamycin, in chemotherapy naive endometrial cancer. Expand
A phase II evaluation of bevacizumab in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group (GOG) Study.
  • C. Aghajanian, M. Sill, +7 authors K. Leslie
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
TLDR
BV appears to have single agent activity in women with recurrent or persistent EMC and warrants further investigation, and 20% increases in the proportion responding or surviving progression-free at 6 months over historical controls. Expand
Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation
TLDR
An integrated analysis of genome-wide expression and copy-number data for primary endometrial carcinomas with extensive clinical and histopathological data distinguished 2 major clusters with strikingly different phenotypes, including significant differences in disease-free survival. Expand
Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells
TLDR
Observations provide a clear biologic rational to test lapatinib as a single agent or in combination with chemotherapy in endometrial cancer with HER2 overexpression, and expression of EGFR, its ligands, HER3, AR, and post-EMT markers warrant further evaluation. Expand
HER‐2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications
TLDR
Targeting HER-2/neu may be beneficial for a select group of patients with UPSC, and samples are being evaluated for Herceptin-induced over expression by fluorescence in situ hybridization (FISH) and immunohistochemical analysis. Expand
Molecular and pathologic aspects of endometrial carcinogenesis.
  • J. Hecht, G. Mutter
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2006
TLDR
The precursor lesion of type I endometrioid cancer and the role of genetics and estrogen in its progression are defined and the genetic aspects of endometrial carcinogenesis and progression are reviewed. Expand
A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer
TLDR
A trial of single agent AP23573, a novel mTOR inhibitor, may result in clinical benefit with fewer side effects in patients with progressive endometrial cancer who may have had up to 2 prior regimens of cytotoxic chemotherapy. Expand
...
1
2
3
4
5
...